Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

16.98 -0.64 (-3.66%)
Streaming Delayed Price Updated: 2:54 PM EDT, Jun 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 753,879
Open 17.44
Bid (Size) 16.96 (100)
Ask (Size) 16.99 (100)
Prev. Close 17.62
Today's Range 16.60 - 17.60
52wk Range 13.18 - 34.29
Shares Outstanding 9,587,155
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗
Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
-44.7%
-44.7%
1 Month
+26.5%
+26.5%
3 Month
-43.9%
-43.9%
6 Month
-46.0%
-46.0%
1 Year
+21.5%
+21.5%

More News

Read More
News headline image
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
From Viridian Therapeutics, Inc.
Via Business Wire
Which stocks are gapping on Tuesday? ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Amgen’s Subcutaneous TEPEZZA Data Sets New Gold Standard for Thyroid Eye Disease Treatment
Via MarketMinute
News headline image
Amgen Reclaims the Lead in Thyroid Eye Disease with Superior Subcutaneous TEPEZZA Data
Via MarketMinute
Topics Intellectual Property
Which stocks are moving on Monday? ↗
Via Chartmill
News headline image
Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones
Via MarketMinute
Topics Intellectual Property
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
Here are the top movers in Monday's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Monday's session. ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
Via The Motley Fool
News headline image
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗
Via The Motley Fool
News headline image
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗
Via The Motley Fool
News headline image
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
VR Adviser Adds Over 1 Million Savara Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Viridian Therapeutics, Inc. - Common Stock publicly traded?
Yes, Viridian Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Viridian Therapeutics, Inc. - Common Stock trade on?
Viridian Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Viridian Therapeutics, Inc. - Common Stock?
The ticker symbol for Viridian Therapeutics, Inc. - Common Stock is VRDN on the Nasdaq Stock Market
What is the current price of Viridian Therapeutics, Inc. - Common Stock?
The current price of Viridian Therapeutics, Inc. - Common Stock is 16.98
When was Viridian Therapeutics, Inc. - Common Stock last traded?
The last trade of Viridian Therapeutics, Inc. - Common Stock was at 06/01/26 02:54 PM ET
What is the market capitalization of Viridian Therapeutics, Inc. - Common Stock?
The market capitalization of Viridian Therapeutics, Inc. - Common Stock is 162.74M
How many shares of Viridian Therapeutics, Inc. - Common Stock are outstanding?
Viridian Therapeutics, Inc. - Common Stock has 163M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.